BR112017027614A2 - anticorpos e método de direcionamento da terapia para um câncer. - Google Patents

anticorpos e método de direcionamento da terapia para um câncer.

Info

Publication number
BR112017027614A2
BR112017027614A2 BR112017027614A BR112017027614A BR112017027614A2 BR 112017027614 A2 BR112017027614 A2 BR 112017027614A2 BR 112017027614 A BR112017027614 A BR 112017027614A BR 112017027614 A BR112017027614 A BR 112017027614A BR 112017027614 A2 BR112017027614 A2 BR 112017027614A2
Authority
BR
Brazil
Prior art keywords
antibodies
cancer
targeting therapy
csf
human
Prior art date
Application number
BR112017027614A
Other languages
English (en)
Inventor
Ries Carola
Klein Christian
CALIGARIS-CAPPIO Federico
GALLETTI Giovanni
Teresa Sabrina BERTILACCIO Maria
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15173638.6A external-priority patent/EP3108897A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112017027614A2 publication Critical patent/BR112017027614A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção diz respeito a linfocitose induzida por anti-csf-1r em linfomas e leucemias e a uma terapia combinada com anticorpos que se ligam ao csf-1r humano e anticorpos que se ligam ao cd20 humano.
BR112017027614A 2015-06-24 2016-06-23 anticorpos e método de direcionamento da terapia para um câncer. BR112017027614A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15173638.6A EP3108897A1 (en) 2015-06-24 2015-06-24 Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
EP16151129 2016-01-13
PCT/EP2016/064611 WO2016207312A1 (en) 2015-06-24 2016-06-23 Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias

Publications (1)

Publication Number Publication Date
BR112017027614A2 true BR112017027614A2 (pt) 2018-08-28

Family

ID=56263686

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017027614A BR112017027614A2 (pt) 2015-06-24 2016-06-23 anticorpos e método de direcionamento da terapia para um câncer.

Country Status (17)

Country Link
US (1) US20180222985A1 (pt)
EP (1) EP3313442B1 (pt)
JP (1) JP6811733B2 (pt)
KR (1) KR20180012873A (pt)
CN (1) CN107847592B (pt)
AU (1) AU2016282877A1 (pt)
BR (1) BR112017027614A2 (pt)
CA (1) CA2987716A1 (pt)
CL (1) CL2017003295A1 (pt)
CR (1) CR20170537A (pt)
HK (1) HK1252860A1 (pt)
IL (1) IL256135A (pt)
MX (1) MX2017016651A (pt)
PE (1) PE20181050A1 (pt)
RU (1) RU2018102575A (pt)
WO (1) WO2016207312A1 (pt)
ZA (1) ZA201708074B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
MX2019011748A (es) 2017-04-01 2020-01-23 Beijing hanmi pharm co ltd Anticuerpo biespecífico heterodimérico tipo estructura de anticuerpo natural anti-pd-l1/anti-pd-1 y preparación del mismo.
US20200071417A1 (en) 2017-04-19 2020-03-05 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
PE20200738A1 (es) 2017-08-08 2020-07-23 Hoffmann La Roche Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de celulas b grandes difusas (dlbcl)
US20200377571A1 (en) 2017-12-08 2020-12-03 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
CN109053888B (zh) * 2018-07-18 2020-06-19 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及其用途
CN109053886B (zh) * 2018-07-18 2020-07-28 博奥信生物技术（南京）有限公司 抗人csf-1r单克隆抗体及用途
JP7465272B2 (ja) 2018-09-27 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58420B1 (sr) * 2003-11-05 2019-04-30 Roche Glycart Ag Cd20 antitela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
BRPI0615397B1 (pt) * 2005-08-26 2023-10-03 Roche Glycart Ag Anticorpo anti-cd20, composição farmacêutica que o contém e uso do mesmo
MY159679A (en) * 2009-12-10 2017-01-13 Hoffmann La Roche Antibodies binding preferentially human csf1r extracellular domain 4 and their use
AR080698A1 (es) * 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
CA2839513A1 (en) * 2011-07-06 2013-01-10 Morphosys Ag Therapeutic combinations of anti - cd20 and anti - gm - csf antibodies and uses thereof
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
AR097584A1 (es) * 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano

Also Published As

Publication number Publication date
KR20180012873A (ko) 2018-02-06
PE20181050A1 (es) 2018-07-03
CL2017003295A1 (es) 2018-06-01
JP6811733B2 (ja) 2021-01-13
CA2987716A1 (en) 2016-12-29
US20180222985A1 (en) 2018-08-09
CN107847592B (zh) 2022-01-21
EP3313442B1 (en) 2019-10-16
EP3313442A1 (en) 2018-05-02
IL256135A (en) 2018-02-28
WO2016207312A1 (en) 2016-12-29
MX2017016651A (es) 2018-05-14
CN107847592A (zh) 2018-03-27
CR20170537A (es) 2018-02-20
AU2016282877A8 (en) 2018-01-18
JP2018525339A (ja) 2018-09-06
HK1252860A1 (zh) 2019-06-06
AU2016282877A1 (en) 2018-01-04
RU2018102575A (ru) 2019-07-25
ZA201708074B (en) 2018-11-28

Similar Documents

Publication Publication Date Title
BR112017027614A2 (pt) anticorpos e método de direcionamento da terapia para um câncer.
CO2017010618A2 (es) Anticuerpos contra icos
CY1122602T1 (el) Αντιμετωπιση των nafld και nash
AR101697A1 (es) Terapia de combinación de inmunocitocinas variantes de il-2 dirigidas a tumores y anticuerpos contra pd-l1 humana
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
BR112017013176A2 (pt) receptores de antígenos quiméricos e métodos para usá-los
CU20150128A7 (es) Conjugados fármaco-anticuerpo
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
BR112017026027A2 (pt) combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20
BR112017001031A2 (pt) apresentação assistida de janelas de aplicativo
BR112016010271A2 (pt) Anticorpo, composição farmacêutica, método de tratamento, uso de um anticorpo e combinação
AR096183A1 (es) Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-fármaco
BR112015023020A2 (pt) combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas
PE20160753A1 (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
CR20170529A (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2.
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
BR112016024789A2 (pt) métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
CO2019000753A2 (es) Métodos para tratar el cáncer de próstata
BR112015027474A8 (pt) anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo.
BR112018008882A8 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
BR112019006504A2 (pt) regime de dosagem de avelumabe para o tratamento de câncer
MX2019006694A (es) Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
BR112017028012A2 (pt) Terapia combinada com um conjugado anticorpo- fármaco anti-her2 e um inibidor de bcl-2

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing